FY2025 Earnings Forecast for BHC Issued By Zacks Research

Bausch Health Companies Inc. (NYSE:BHC) – Investment analysts at Zacks Research lowered their FY2025 earnings per share estimates for shares of Bausch Health Companies in a research report issued to clients and investors on Monday, January 20th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $4.23 for the year, down from their prior forecast of $4.28. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.73 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2026 earnings at $1.27 EPS and FY2026 earnings at $4.90 EPS.

BHC has been the topic of a number of other research reports. Royal Bank of Canada raised their price target on Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a report on Friday, November 1st. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Finally, Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Bausch Health Companies currently has an average rating of “Hold” and an average target price of $7.75.

Bausch Health Companies Price Performance

Shares of NYSE:BHC opened at $7.73 on Thursday. The stock has a market cap of $2.79 billion, a P/E ratio of -16.09 and a beta of 0.69. Bausch Health Companies has a 1-year low of $3.96 and a 1-year high of $11.46. The firm has a fifty day moving average price of $7.83 and a 200 day moving average price of $7.46.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.10. The business had revenue of $2.51 billion during the quarter, compared to the consensus estimate of $2.42 billion. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The company’s revenue was up 12.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.03 earnings per share.

Institutional Trading of Bausch Health Companies

Institutional investors have recently modified their holdings of the business. DGS Capital Management LLC acquired a new stake in Bausch Health Companies in the fourth quarter valued at $143,000. Merit Financial Group LLC acquired a new stake in shares of Bausch Health Companies in the fourth quarter valued at about $228,000. Sanders Morris Harris LLC boosted its holdings in Bausch Health Companies by 16.0% during the fourth quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company’s stock worth $234,000 after buying an additional 4,000 shares in the last quarter. Northwest & Ethical Investments L.P. boosted its holdings in Bausch Health Companies by 13.0% during the third quarter. Northwest & Ethical Investments L.P. now owns 32,384 shares of the company’s stock worth $264,000 after buying an additional 3,734 shares in the last quarter. Finally, Creative Planning grew its position in Bausch Health Companies by 16.9% during the third quarter. Creative Planning now owns 55,351 shares of the company’s stock worth $452,000 after buying an additional 7,995 shares during the period. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.